{"id":257974,"date":"2026-05-27T17:25:28","date_gmt":"2026-05-27T17:25:28","guid":{"rendered":"https:\/\/www.europesays.com\/se\/257974\/"},"modified":"2026-05-27T17:25:28","modified_gmt":"2026-05-27T17:25:28","slug":"vd-patalar-vikt-av-advance-studien-i-fas-2b-ny","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/257974\/","title":{"rendered":"VD P\u00c5TALAR VIKT AV ADVANCE-STUDIEN I FAS 2B (NY)"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">(Till\u00e4gg: l\u00e4gger till information om n\u00e4r \u00f6vergripande data fr\u00e5n studien v\u00e4ntas i stycke tre)<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget Synact Pharmas vd p\u00e5talar vikten av Advance-studien, d\u00e4r l\u00e4kemedelskandidaten resolmelagon utv\u00e4rderas i en fas 2b-studie vid behandling av ledg\u00e5ngsreumatism (RA).<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">&#8221;Positiv Advance-data \u00e4r den avg\u00f6rande h\u00e4ndelsen som kommer att driva partnersamtal fram\u00e5t. Vi \u00e4r v\u00e4l f\u00f6rberedda&#8221;, skriver Jeppe \u00d8vlesen i vd-ordet av rapporten f\u00f6r det f\u00f6rsta kvartalet 2026.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">\u00d6vergripande data fr\u00e5n den ber\u00f6rda studien v\u00e4ntas i juni 2026.<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Magnus Bernet +46 8 5191 7953<\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nyhetsbyr\u00e5n Direkt<\/p>\n","protected":false},"excerpt":{"rendered":"(Till\u00e4gg: l\u00e4gger till information om n\u00e4r \u00f6vergripande data fr\u00e5n studien v\u00e4ntas i stycke tre) STOCKHOLM (Nyhetsbyr\u00e5n Direkt) Forskningsbolaget&hellip;\n","protected":false},"author":2,"featured_media":257975,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[65],"tags":[72,70,71,34,31,33,32,30,12427],"class_list":["post-257974","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ekonomi","tag-business","tag-economy","tag-ekonomi","tag-se","tag-svenska","tag-sverige","tag-sweden","tag-swedish","tag-synact-pharma"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116647711573096904","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/257974","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=257974"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/257974\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/257975"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=257974"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=257974"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=257974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}